doxycycline/tudca versus standard supportive therapy in transthyretin cardiac amyloidosis
Published 2 months ago • 85 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:04
treatment approaches for al amyloidosis versus attr amyloidosis
-
5:16
the evolution of al amyloidosis therapy
-
1:22
differentiating between amyloidosis and myeloma
-
2:52
gvhd prophylaxis in aml: ptcy versus cni
-
1:39
new clinical trial results in cardiac and peripheral nerve amyloidosis
-
3:36
what are the signs and symptoms of amyloidosis?
-
1:13:17
professor chris fegan chairs a discussion on living well with cll.
-
6:02
difference between doxycycline and minocycline
-
0:46
efficacy of diflunisal for hereditary transthyretin amyloidosis: data from the sveattr registry
-
1:10
the value of close collaboration between cardiologists, hematologists & other mdts in amyloidosis
-
0:52
monitoring, diagnosing & managing cardiotoxicity in al amyloidosis
-
1:54
risk-adapted therapy: three-day versus five-day oral decitabine in patients with mds
-
6:00
association between the v122i ttr variant with heart failure in attr amyloidosis, scd & leukemia
-
1:18
celestial-tncll: ongoing phase iii study of sonrotoclax zanubrutinib vs ven obi for tn cll
-
3:02
the interplay between t-all cells & tecs and the role of tecs in disease progression
-
2:52
assessing the value of various prognostic biomarkers in al amyloidosis
-
3:47
vod: treatment and prevention
-
1:07
an update on astral-3: guadecitabine vs treatment of choice in adults with previously treated mds
-
2:04
results of trial of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in cll
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
2:20
murano: venetoclax rituximab in birc3-mutated r/r cll